uniQure launches $150 million public share offering

uniQure N.V. (NASDAQ: QURE) announced a proposed underwritten public offering of $150 million in ordinary shares, with pre-funded warrants available to certain investors in lieu of ordinary shares, according to a press release from the gene therapy company.

All securities in the offering will be sold by uniQure. The company also intends to grant underwriters a 30-day option to purchase up to an additional $22.5 million in ordinary shares under the same terms.

Leerink Partners and Stifel are serving as bookrunning managers for the offering.

The securities are being offered under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on January 7, 2025. uniQure noted the offering is subject to market and other conditions, and there is no assurance as to whether or when it may be completed, or as to its final size or terms.

uniQure is headquartered in Lexington, Massachusetts and Amsterdam. The company has a gene therapy approved for hemophilia B and a pipeline targeting Huntington's disease, refractory temporal lobe epilepsy, and Fabry disease, among other conditions.

You May Also Be Interested In

• uniQure prices $225 million public offering at $45.50 per share
• FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
• Colony Bankcorp to acquire First Reliance in $163M stock-and-cash deal